Clinical Utility of Rush Venom Immunotherapy: Current Status.

J Asthma Allergy

Department of Respiratory Medicine and Allergic Diseases, University Hospital Centre of Toulouse, Toulouse, France.

Published: January 2020

Hymenoptera venom allergy (HVA) is the leading cause of anaphylactic reactions in adults and the second most common cause in children. Venom immunotherapy (VIT) is used to elicit an immune tolerance against hymenoptera venom in allergic patients and is based on the administration of purified venom extracts regularly for defined periods. The protocols of administration include 2 phases: an up-dosing phase that incrementally reaches the final dose resulting in a protective effect, and a maintenance phase in order to obtain the sustained effect. The goal of this review is to detail the efficacy and the safety of the up-dosing phase also named rush. Pathophysiological mechanisms, indications of VIT and technical aspects of up-dosing protocol are also covered.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6954838PMC
http://dx.doi.org/10.2147/JAA.S200917DOI Listing

Publication Analysis

Top Keywords

venom immunotherapy
8
hymenoptera venom
8
up-dosing phase
8
venom
5
clinical utility
4
utility rush
4
rush venom
4
immunotherapy current
4
current status
4
status hymenoptera
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!